Soon-Shiong’s NantCell raises another $57M for immuno-oncology work

Damian Garde Billionaire entrepreneur Patrick Soon-Shiong's NantCell raised $ 57.3 million in equity to fund its work on treatments that use the immune system to fight cancer, ...

AbbVie and Roche’s cancer drug snags another ‘breakthrough’ tag

Damian Garde AbbVie and Roche's cancer drug venetoclax, awaiting FDA approval, picked up another breakthrough therapy nod from the agency for its potential as part of a combination ...

Supreme Court rebuffs another J&J appeal, leaving $140M failure-to-warn judgment intact

Tracy Staton Johnson & Johnson is zero for two at the U.S. Supreme Court this month. Last week, the court refused to weigh its final appeal against a $ 124 million penalty ...

Eleven Bio faces cash crunch as lead drug flunks another PhIII

John Carroll FierceBiotech News

Sanofi commits €400M to another cancer R&D pact, this time with Innate Pharma

John Carroll Less than a year after Sanofi downsized its cancer drug R&D operations, the pharma giant has struck back-to-back deals to launch new immuno-oncology drug programs, ...

Another Chinese biopharma lines up for a billion-dollar IPO

Damian Garde Chinese drugmaker Simcere Pharmaceutical is plotting a Hong Kong IPO worth up to $ 1 billion, according to reports, joining a slew of local biopharma companies headed ...

Globalization: Another year closer to a worldwide network

John Carroll When AstraZeneca announced its move to create its third R&D hub in China, the pharma giant was following in the paths of some major rivals. It also represented another ...

M&A: Buckle your seat belts for another big round of deals

John Carroll With valuations down, buyouts and licensing deals become even more attractive. They're already a requirement. Anyone with a casual acquaintance with the state of Big ...

Wellcome invests $38M in another gene therapy startup, targeting hemophilia

Damian Garde The Wellcome Trust's investment arm is putting up £25 million ($ 38 million) to launch a new company developing a potential one-time treatment for hemophilia ...

Mesoblast disappoints in another below-the-range biotech IPO

Damian Garde Australian biotech Mesoblast priced its U.S. IPO below expectations, raising $ 60 million to support its pipeline of cell therapies. FierceBiotech News

Biotech notches another $2B VC quarter, but can it last?

Damian Garde Biotech venture capital investments remain on pace for a record year after racking up another $ 2 billion in the third quarter, but some current shakiness in the public ...

Anthera hits another setback as its Japanese partner quits on blisibimod

Damian Garde Anthera Pharmaceuticals is back on the hunt for a partner in Asia after Japanese drugmaker Zenyaku pulled the plug on the pair's collaboration, clouding the future ...
Page 1 of 712345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS